Rye Brook, N.Y., Oct. 28, 2020 – Curemark, is pleased to announce the appointment of Leigh Morgan of Seattle, WA to its Board of Directors. Ms. Morgan brings to the board a wealth of leadership that spans the corporate, public, philanthropic, and higher education sectors. She served as the COO of the Bill and Melinda Gates Foundation, and Vice President/Global Head of HR Products at Genentech/Roche biopharma. She has served as Associate Chancellor at the University of California San Francisco (UCSF) and currently is the Vice Chair of the Board of the Fred Hutchinson Cancer Research Center in Seattle and a board member of the Fuqua School of Business Center for Advancement of Social Entrepreneurship at Duke University.
“We are honored to have Leigh as a new Board member,” states Dr. Joan Fallon Curemark’s CEO. “She brings with her a wealth of knowledge and experience that will be valuable for Curemark in the months ahead as we prepare for our next stage of growth and beyond. Her knowledge of biotech/pharma, scaling, leading global brands and understanding the public healthcare sector will help guide us to the ultimate goal of getting our Autism drug to everyone who needs it worldwide.”
“I’m excited to join the Curemark board as its first independent Director,” said Ms. Morgan. “I am deeply inspired by Dr. Fallon’s vision, and the entire team’s dogged commitment to scientific innovation and finding effective, safe, and ground-breaking therapies for patients around the globe who suffer from autism and other neurological disorders.”
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of autism, schizophrenia and Parkinson’s disease, ADHD and addiction. For additional information, please visit our website at http://www.curemark.com or follow @Curemark on Twitter.
This press release includes both historical facts and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. In some cases, forward-looking statements can be identified by words such as “may,” “will,” “should,” “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” “predict,” “potential,” the negative of such words, variations of such words and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. These risks and uncertainties include, among other things, uncertainties inherent in (i) research and development, (ii) the building of Curemark, LLC’s patent portfolio and protection of its intellectual property, (iii) the conduct of clinical trials, (iv) obtaining the requisite approval of regulatory authorities to market and sell Curemark LLC’s product candidates, (v) decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of Curemark LLC’s product candidates, and (vi) competitive developments. Readers should not place undue reliance on any forward-looking statements, which are based on Curemark, LLC’s current expectations of future events and speak only as of the date they are made. Except as may be required by law, Curemark, LLC undertakes no obligation to update any forward-looking statements contained in this press release to reflect any change in Curemark, LLC’s expectations or any change in information, events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.